Pharmacological induction of fetal hemoglobin in sickle cell disease and β-thalassemia

Seminars in Hematology

Volumn 38, Issue 4, 2001, Pages 367-373

  Atweh, George F ^a   Loukopoulos, Dimitris ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLOBIN; ARGININE BUTYRATE; AZACITIDINE; BUTYRIC ACID DERIVATIVE; DEOXYHEMOGLOBIN; GAMMA GLOBIN; HEMOGLOBIN E; HEMOGLOBIN F; HEMOGLOBIN S; HYDROXYUREA; ISOBUTYRAMIDE; RECOMBINANT ERYTHROPOIETIN; SODIUM PHENYLBUTYRATE; UNCLASSIFIED DRUG;

BETA THALASSEMIA; CLINICAL TRIAL; DNA METHYLATION; DRUG EFFICACY; ERYTHROID CELL; HUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; REVIEW; SICKLE CELL ANEMIA; THALASSEMIA MAJOR;

EID: 0034772589     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90031-9     Document Type: Article

References (59)

1. Cooperative enhancement of F-cell formation in baboons treated with erythropoietin and hydroxyurea
2. Successful use of hydroxyurea in thalassemia major
3. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease
4. The relative rates of fetal and adult hemoglobin synthesis in cord blood of infants of insulin-dependent diabetic mothers
5. Sickle cell anemia and trait in a population in southern India
6. Induction of fetal hemoglobin in sickle cell disease
7. Hydroxyurea and sickle cell anemia: Clinical utility of a myelosuppressive "switching" agent: The Multicenter Study of Hydroxyurea in sickle cell anemia
8. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia
9. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia
10. Hematological responses to hydroxyurea therapy in multi-transfused thalassemic children
11. Oral sodium phenylbutyrate therapy in homozygous thalassemia: A clinical trial
12. α-Amino-N-butyric acid stimulates fetal hemoglobin in the adult
13. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons
14. Oral isobutyramide therapy in patients with thalassemia intermedia: Results of a phase II open study
15. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate
16. Hydroxyurea for the treatment of sickle cell disease
17. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis on β-thalassemia/hemoglobin E disease
18. Hydroxyurea therapy in paraparesis and caude equina syndrome due to extramedullary haematopoiesis in thalassemia: Improvement of clinical and haematological parameters
19. Activation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytidine and sodium butyrate
20. Pharmacologic treatment of thalassemia intermedia with hydroxyurea
21. A complex containing N-CoR, mSin 3 and histone deacetylase mediates transcriptional repression
22. Hydroxyurea and hemin affect both the transcriptional and post-transcriptional mechanisms of some globin genes in human adult erythroid cells
23. A case of spinal cord compression by extramedullary hemopoiesis in a thalassemia patient: A putative role for hydroxyurea?
24. Effect of hydroxyurea in sickle cell anemia: A clinical trial in children and teenagers with severe sickle cell anemia and sickle cell/β-thalassemia
25. 2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia
26. Histone deacetylases associated with the mSin 3 corepressor mediate mad transciptional repression
27. Augmentation of fetal hemoglobin production in anemic monkeys by hydroxyurea
28. 5-Azacytidine increases γ-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia
29. Current status of thalassemia and the sickle cell syndromes in Greece
30. Hydroxyurea therapy in thalassemia
31. Reduction of the clinical severity of sickle cell/β-thalassemia with hydroxyurea: The experience of a single center in Greece
32. Clinical trials with hydroxyurea and recombinant human erythropoietin
33. Pharmacological manipulation of fetal hemoglobin synthesis in patients with severe beta-thalassemia
34. Levels of fetal hemoglobin necessary for treatment of sickle cell disease
35. Treatment of thalassemia major with phenylbutyrate and hydroxyurea
36. Administration of hydroxyurea in patients with sickle cell disease induces an inappropriately high secretion of erythropoietin
37. Natural history of sickle cell anemia in Saudi Arabs
38. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders
39. Delay in the fetal globin switch in infants of diabetic mothers
40. Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching
41. Mortality in sickle cell disease: Life expectancy and risk factors for early death
42. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia
43. Pain in sickle cell disease: Rates and risk factors
44. Sparing effect of hemoglobin F and hemoglobin A 2 on the polymerization of hemoglobin S at physiological ligand saturations
45. The role of recombinant human erythropoietin in the treatment of thalassemia
46. Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassemia
47. Clinical and hematological response to hydroxyurea in a patient with Hb Lepore/β-thalassemia
48. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea
49. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease
50. Tissue-specific DNA methylation in a cluster of rabbit beta-like globin genes
51. Extended therapy with intravenous arginine butyrate in patients with β-hemoglobinopathies
52. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia
53. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea
54. Absence of cross-resistance to the HbF stimulating activities of butyrate and hydroxyurea
55. Progressive pulmonary hypertension and pulmonary insufficiency in sickle cell patients who respond to hydroxyurea
56. Treatment of thalassemia intermedia with hydroxyurea
57. Erythroid progenitor proliferation is stimulated by phenoxyacetic and phenylalkyl acids
58. The significance of the paucity of sickle cells in newborn Negro infants
59. Hydroxyurea therapy in beta thalassemia intermedia: Improvement in haematological parameters due to enhanced beta-globin synthesis